Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change

Stock Information for Armata Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Armata Pharmaceuticals Inc.

Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA® (Icosapent Ethyl) in Europe
Amarin Reports First Quarter 2025 Financial Results
Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement
Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025
Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors
Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist
Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program
Amarin Reports Fourth Quarter Financial Results & Business Update and Announces Important Corporate Action 

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.